Sport Medicine Market Exclusive Profitable Comprehensive Report Cover COVID-19 Updates | Smith & Nephew plc, Stryker Corporation

The MarketWatch News Department was not involved in the creation of this content.

Nov 24, 2020 (WiredRelease via Comtex) —
A consciously conceived and designed business intelligence report titled Global Sport Medicine market 2020 by Manufacturers, Type, and Application, Forecast to 2029 by MarketResearch.biz discloses a succinct analysis of the regional spectrum, market size, and revenue forecast about the market. This report sheds light on the vital developments along with other events happening in the global Sport Medicine market which is marking on the enlargement and opening doors for outlook growth in the coming years.

This is the latest report, covering the current COVID-19/Corona Virus pandemic impact on the market which has affected every aspect of life globally. This has brought along several changes in market conditions and the Business areas. The rapidly changing market scenario and initial and future assessment of the impact are covered in the Sport Medicine market report.

For All-Inclusive Information: Download a FREE sample copy of Sport Medicine Market Report Study 2020-2029 at https://marketresearch.biz/report/sport-medicine-market/request-sample

(Our FREE SAMPLE COPY of the report gives a brief introduction to the research report outlook, list of tables and figures, Impact Analysis of COVID-19, TOC, an outlook to key players of the market and comprising key regions.)

Competitive Analysis:

The major companies are exceedingly focused on innovation in Sport Medicine production technology to enhance ledge life and efficiency. The best long-term development path for Sport Medicine market can be caught by guaranteeing financial pliancy to invest in the optimal strategies and current process improvement.

Key manufacturers are included based on the company profile, sales data and product specifications, etc: Smith & Nephew plc, Stryker Corporation, Johnson & Johnson Private Limited, Arthrex Inc., Conmed Corporation, Zimmer Biomet Holdings, Inc., Breg, Inc., Mueller Sports Medicine, Inc., DJO Global, Inc., Wright, Medical Group N.V.

Each manufacturer or Sport Medicine market player’s growth rate, gross profit margin, and revenue figures is provided in a tabular, simple format for few years and an individual section on Sport Medicine market recent development such as collaboration, mergers, acquisition, and any new service or new product launching in the market is offered.

Sport Medicine Market Segmentation Outlook By product, application, and region:

Global sport medicine market segmentation, by product:
Body Reconstruction and Repair Products
Body Support and Recovery Product
Body Monitoring and Evaluation
Accessories

Global sport medicine market segmentation, by application:
Knee Injuries
Hip Injuries
Shoulder Injuries
Ankle & Foot Injuries
Back & Spine Injuries
Elbow & Wrist Injuries
Other Injuries

Download Now And Browse Complete Information On The COVID 19 Impact Analysis On Sport Medicine Market: https://marketresearch.biz/report/sport-medicine-market/covid-19-impact

Regional Analysis:On the idea of geography, the Sport Medicine Market report covers statistics for a couple of geographies inclusive of, North America (U.S., Mexico, Canada) South America (Argentina, Brazil) The Middle East & Africa (South Africa, Saudi Arabia) Asia-Pacific (China, Japan, India, Southeast Asia) Europe (U.K., Spain, Italy, Germany, France, Russia)

In addition, The following years considered for this study to forecast the global Sport Medicine market size are

Read more

A review of Traditional Chinese herbal medicine in management of COVID-19

The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected over 59.65 million people worldwide and claimed the lives of over 1.4 million. The virus, first detected in late December 2019 in Wuhan, China, is the most significant public health problem since the 1918 Spanish flu pandemic. There are no effective and safe drugs that can be used to treat COVID-19 disease nor vaccine to prevent SARS-CoV-2 infection. Since the first cases were detected in Wuhan, several traditional Chinese herbal medicines have been used to treat this infection.

Now researchers led by David Lee from Bio-Organic and Natural Research Laboratory, McLean Hospital, Harvard Medical School, Belmont have summarized the experiences with the use of traditional Chinese herbal medicines for the management of COVID-19. Their study titled, “Traditional Chinese herbal medicine at the forefront battle against COVID-19: Clinical experience and scientific basis,” was published in the January 2021 issue of the journal Phytomedicine.

Study: Traditional Chinese herbal medicine at the forefront battle against COVID-19: Clinical experience and scientific basis. Image Credit: Dragon Images / Shutterstock

Background

China has a rich history of traditional herbal medicines. Traditional Chinese herbal medicine (TCM) has been used for over 5,000 in over 300 epidemics that the nation has faced. When the COVID-19 pandemic emerged early this year, treatment with TCM was reported to have been used with over 90 percent efficacy.

Study particulars

This study was a systematic review of several traditional Chinese herbal medicines that were used in Wuhan,  looking at their efficacy in the management of COVID-19. At present, patients admitted to hospitals (except TCM hospitals) are primarily treated with western medicine as frontline treatment.

Principles of TCM use

The western medications used include antibiotics and painkillers. At present, over 100 herbal TCM formulae are available for use in epidemic related infections. Authors write, “TCM is now credited for the successful battle against COVID-19 in China”.

The ancient Chinese medical text Huangdi Neijing explains that 12 meridian lines run through the human body and help balance the immune system and provide good health. The lung meridian line interconnects with the large intestine functionally and controls the body fluid (water). The researchers write, “Expelling phlegm and relaxing the bowels with laxatives are common methods for treating lung diseases. Therefore, maintaining a smooth and open channel is an important function served by the lung meridian line.” Treatment of COVID-19 is basically to “expel the toxic moisture from the upper respiratory system and to improve intestinal obstruction.” They added that the TCM method of treatment tries to maintain the balance of the lung meridian system and to restore the lung and large intestine balance using acupuncture and herbal medicine.

Treatment of COVID-19 using TCM

TCM has been used as a first-line treatment for COVID-19 disease since the emergence of SARS-CoV-2. Qingfei Paidu decoction for example, has been used in a three-day course leading to an over 90 percent efficacy.

The team of researchers wrote, “The Chinese government announced that TCM is one of the recommended therapeutic options for the treatment of COVID-19 in the third version COVID-19 treatment guidelines, published on January

Read more

Michigan Medicine restricts visitors for adult patients as COVID-19 cases climb

ANN ARBOR – Michigan Medicine has updated its visitor policy with tightened restrictions in order to keep patients and staff safe as COVID-19 cases surge around the state.

As of Wednesday, no visitors will be permitted with adult patients in the health system’s hospitals, unless medically necessary.

Exceptions to the new restrictions include end-of-life care, labor and delivery and other scenarios which are listed here.

According to Michigan Medicine, the new policy change includes restrictions already announced:

  • No visitors are allowed with adult emergency department patients, except when medically necessary.
  • At C.S. Mott Children’s Hospital, two visitors are allowed for pediatric patients. But family and other visitors are required to wear a mask (covering their mouth and nose) at all Michigan Medicine properties. This includes in a patient room and throughout the facility. Patients who can tolerate a mask must wear one when a health care worker is present in their room.
  • In clinics, no visitors will be allowed for adult patients unless the patient has a cognitive or physical impairment that requires assistance. One primary caregiver is allowed to accompany each pediatric patient to an appointment, unless an additional aide or assistant is required.

 Like what you’re reading? Sign up for our email newsletter here!

“COVID-19 transmission rates continue to climb in the community,” Laraine Washer, Michigan Medicine’s medical director of infection prevention and epidemiology said in a statement. “Our top priority is the safety of our patients and staff, and to minimize the spread of disease, we need to take this additional step.

“We know this is difficult for our patients and their families and friends. But we need to continue to keep our Michigan Medicine facilities safe for all of our patients.”

Since the pandemic began in March, Michigan Medicine has been taking steps to keep staff and patients safe, including screening patients for symptoms, cleaning and disinfecting facilities, moving furniture to observe social distancing and following the latest guidelines to minimize infections.

“Limiting the risk of transmission of infection has always been a critical priority at Michigan Medicine,” Washer said in a statement. “And I want to reassure the public that if you need health care for a new problem or for continuing care of a chronic problem, you should not put it off.

“We have teams dedicated to keeping our patients and staff safe in our buildings. It is important to not delay emergency or chronic care.”

Washer urged people to avoid Thanksgiving gatherings this year with those outside your household.

“The best advice to limit risk is to continue to avoid gathering with people outside your household even if it is Thanksgiving,” she said in a statement. “If you are reporting to work, don’t have potlucks or share meals in close proximity with your co-workers: you can’t eat without taking off your mask, and that brief period of not wearing a mask could be enough to open the door to disease spread.

“We need everyone’s help with this. A large surge of

Read more

UChicago Medicine and UIC researchers to study expanded access to rapid COVID-19 testing

Researchers at the University of Chicago Medicine and the University of Illinois at Chicago (UIC) are launching an investigational study to determine the effects of increased education and access to rapid, FDA-approved COVID-19 testing on community perceptions, access, and use of COVID-19 testing resources.

The study will be funded by $2M in support from the National Institutes for Health RADx-UP program. A part of the Rapid Acceleration of Diagnostics (RADx) initiative, the RADx Underserved Populations (RADx-UP) program supports research that aims to better understand COVID-19 testing patterns among underserved and vulnerable populations; strengthen the data on disparities in infection rates, disease progression and outcomes; and develop strategies to reduce the disparities in COVID-19 testing.

The research will be led by Ayman Al-Hendy, MD, professor of obstetrics and gynecology at UChicago Medicine, and Renee Taylor, PhD, professor of occupational therapy and Nahed Ismail MD, PhD, D(ABMM), D(ABMLI), professor of pathology and medical director of clinical microbiology at the University of Illinois at Chicago. The investigators plan to leverage existing university-community partnerships and expertise in clinical microbiology, community engagement, and epidemiological infrastructures to expand access to rapid COVID-19 testing.

“There are testing deserts in Chicago, where many people don’t have easy or affordable access to testing,” said Taylor. “We can reach individuals who maybe don’t have health insurance or are concerned about having a COVID-19 test on their medical record and provide them with an easy and private opportunity to get tested.”

The project includes collaboration with community members to co-create advertisements to recruit other participants into the trial as well as a mobile health web app, called the mHealth Literacy and Outreach Suite, that will allow individuals to not only privately order testing, but also learn how to prevent the spread of COVID-19 and care for themselves if they fall ill.

Investigators are also sending out kits so participants can collect their own samples and send them to be tested at UIC. Sample collection can be performed rapidly at home with a nasal swab, without the discomfort of the typical nasopharyngeal swab, before sending the sample to the central lab for testing.

The team hopes that the privacy offered by these options, as well as the community advocacy, will help improve the public perception of receiving a COVID-19 test.

“Many people don’t trust the test, are concerned about the expense, or are worried that they’ll be forced out of work or forced to isolate if they have a positive test, which is creating a lot of stigma,” said Ismail. “We need to expand our testing in a community setting where people have some privacy, and the mHealth Suite provides that, as well as overcoming issues of cost.”

Al-Hendy credits the skills of the interdisciplinary team and their pooled community networks for making this collaborative effort possible. “The collaboration between UIC and UChicago Medicine will allow this project to reach many underserved populations,” he said. “Our two institutions already both have robust relationships within our local communities, which will help expand the

Read more

Vir Biotech CEO Says His Covid-19 Medicine Offers Promise for Next Outbreak

(Bloomberg) — Vir Biotechnology Inc.’s stock has lost some of its luster after quadrupling earlier this year as competition heats up for Covid-19 antibody therapies. Yet its chief executive officer is looking ahead to the next viral scourge.

Loading...

Load Error

With two well-heeled competitors ahead of it, Vir has pared a February surge to a still impressive 122% leap this year. Eli Lilly & Co.’s antibody treatment received an emergency use authorization on Nov. 9 and Regeneron Pharmaceuticals Inc.’s therapy got its nod over the weekend. Vir’s medicine is unique because it targets a variety of coronaviruses, CEO George Scangos said.

It “has the potential not only to be effective against Covid-19, but it has a reasonable chance of also being effective against the next coronavirus outbreak,” Scangos said in an interview. An interim look at late-stage data for VIR-7831 is expected in January.

Regeneron has touted its two-antibody cocktail as being better than single-antibody treatments like those from Lilly or Vir. Yet Scangos, a former Biogen Inc. chieftain, said that while Lilly and Regeneron’s medicines block the ability of the virus to infect cells, the virus could evade these antibodies by mutating.

‘Babe Ruth’

“Would you rather have two random baseball players or Babe Ruth?,” he said. “It’s not just the number but the quality and the characteristics of the antibody.”

Vir’s antibody was developed not from a Covid-19 patient but from one who’d recovered from severe acute respiratory syndrome, or SARS, which is also caused by a coronavirus. The company chose an antibody that also works against Covid-19 and Scangos postulates that it responds to something in the SARS and Covid viruses that hasn’t changed over years of viral evolution.

He also sees potential advantage for Vir’s antibody in its engagement of part of the immune system where Lilly and Regeneron’s molecules have had less potent activity.

Baird’s Madhu Kumar, the only analyst with a sell-equivalent rating on Vir, is skeptical. He said this particular component of Lilly and Regeneron’s antibodies may be what led to some safety signals and “could trigger inflammatory cascades that could be detrimental to patients.” This particularly concerns hospitalized patients, which Vir is still studying, Kumar told Bloomberg.

Email requests for comment to Lilly and Regeneron weren’t returned.



chart: Vir rally on antibodies hit by other's Covid scientific advances


© Bloomberg
Vir rally on antibodies hit by other’s Covid scientific advances

Much of Kumar’s skepticism is tied to Vir’s valuation. Even after the stock pulled way back from a Feb. 27 record, it’s still has more than doubled this year. He’s also wary of the market for antibodies in general because successful vaccine results from Pfizer Inc. and partner BioNTech SE as well as Moderna Inc. have blunted its longer term “tail value.”

Outside of Covid-19, Kumar has a positive view on Vir. “There’s a real company behind this,” he said, calling out Vir’s hepatitis B RNAi platform.

Others on Wall Street take a more optimistic view with five analysts deeming it a buy, and one with a hold rating. The average analyst price

Read more

New COVID-19 Vaccine Unit Opens at Montefiore and Albert Einstein College of Medicine

The vaccine unit opening comes as global coronavirus infections are rising sharply, with nearly 200,000 cases reported daily in the United States. Montefiore’s goal is to ensure more than half of all trial participants are adults most affected by COVID-19 with a focus on people older than 65. Across the country, older individuals and communities of color have been disproportionately impacted by the pandemic.

“Montefiore and Einstein have a legacy of providing inclusive access to cutting edge care,” said Andrew D. Racine, M.D., Ph.D., system senior vice president and chief medical officer at Montefiore and professor of pediatrics at Einstein. “By ensuring that historically underrepresented patients are included in COVID-19 vaccination research, this effort will help ensure the efficacy and safety of vaccines for these underrepresented patient groups.”

The new vaccine unit builds on Montefiore and Einstein’s leadership conducting COVID-19 trials and providing lifesaving clinical care to thousands of people in the community and has already started enrolling people in the AstraZeneca-Oxford vaccine AZD1222 trial. Dr. Zingman is the principal investigator at Montefiore for the vaccine, which is one of 13 COVID-19 vaccines in phase III trials and the first to be evaluated at Montefiore and Einstein. He was also the principal investigator at Montefiore and Einstein for the ACTT-1 and ACTT-2 National Institutes of Health trials, which evaluated remdesivir (now FDA-approved as a treatment for people hospitalized with COVID-19) and remdesivir plus baricitinib, respectively. 

Since March, physician-scientists at Montefiore and Einstein have studied COVID-19’s impact on almost every major health condition, ranging from asthma to cancer; examined health inequities in local communities; and helped determine which treatments work best against COVID-19.

Among its notable research, Montefiore and Einstein faculty:

–  Published the first major U.S. study on the use of steroids, which confirmed the findings of the large-scale British RECOVERY trial showing that steroids are effective in treating COVID-19; the study also revealed which patients can be harmed by steroids

–  Led the first-ever study comparing the immune responses of adults and children with COVID-19 and detected key differences that may explain why children have milder disease than adults

–  Led the development of a monoclonal antibody therapy to neutralize COVID-19—and potentially other emerging coronaviruses—clinical trials will begin in December

–  Created a blood test for detecting COVID-19 antibodies, used clinically and for research

–  Launched the first randomized, placebo-controlled, double-blind trial of convalescent plasma with NYU Langone Medicine Center, which has expanded to include the University of Miami and the University of Texas-Houston, among other locations across the country

–  Was the first New York City medical center to enroll participants in the ACTT-1 remdesivir trial and the second highest enrolling site worldwide

–  Will offer the first randomized controlled trial of dexamethasone versus baricitinib (NIAID ACTT-4 study) for the hyperinflammatory state in COVID-19

“Words cannot express my appreciation for the many people who worked so hard to establish the new COVID-19 vaccine unit, making sure underrepresented communities will have access to the most promising

Read more

Here’s how the U.S. government plans to distribute the first Covid-19 vaccines.

In the wake of a steady stream of positive results indicating the effectiveness of several coronavirus vaccines, the official in charge of the federal coronavirus vaccine program explained on Sunday news shows how the vaccines might be distributed to Americans as early as next month.

Dr. Moncef Slaoui, head of the administration’s Operation Warp Speed, said that within 24 hours after the Food and Drug Administration approves a vaccine, doses will be shipped to states to be distributed. “Within 48 hours from approval,” the first people would likely receive injections, Dr. Slaoui said on ABC’s “This Week With George Stephanopoulos.”

Two companies, Pfizer and Moderna, announced this month that their vaccines were about 95 percent effective, and Pfizer formally submitted an application to the F.D.A. for emergency approval. Regulators at the agency will spend about three weeks reviewing the application. On Dec. 10, an outside advisory board on vaccines will meet to discuss the application, and the agency is expected to make a decision shortly after that meeting. Moderna is expected to submit its own application soon.

Even if the first vaccine is authorized in mid-December, officials and company representatives have estimated that there will only be enough doses available to treat about 22.5 million Americans by January. Each vaccine requires two doses, separated by several weeks.

Dr. Slaoui said vaccines would be shipped to states, proportioned according to their population, and that states would decide how and where to distribute the doses. He said that likely within a day after a vaccine receives F.D.A. authorization, a committee at the Centers for Disease Control and Prevention would issue recommendations for which groups should be first to receive a vaccine.

High-priority groups are likely to include frontline medical workers and residents of nursing homes. Dr. Scott Gottlieb, a former F.D.A. commissioner, said on the CBS show “Face the Nation” that those groups would likely be followed by other older adults and then expanded to younger adults in the spring. Both he and Dr. Slaoui estimated that tens of millions of adults could be vaccinated by sometime in May.

Immunizations for children would follow. Dr. Slaoui said on the CNN show “State of the Union” that the youngest participants in the clinical trials so far have been 12 to 14 years old and that approval for younger children and toddlers would likely not occur until late in 2021, after clinical trials for those age groups are conducted.

On “Face the Nation,” Larry Merlo, the chief executive of CVS Health, said that pharmacists and other medical staff from CVS plan to immunize residents of more than 25,000 long-term care facilities, beginning about 48 hours after a vaccine is approved. He said that for several years, CVS has been going to nursing homes to administer the seasonal flu vaccine, so “we have the systems, we have the processes, and we have built the logistics directly for the Covid vaccine.”

Mr. Merlo, whose company runs 10,000 pharmacies across the country, also said as the supply

Read more

COVID-19, Seizures and Epilepsy | For Better

For people with epilepsy, the neurological complications of COVID-19 are of special importance. Although our understanding of the virus continues to evolve and change, some insights have emerged.

(Getty Images)

The novel coronavirus affects multiple systems in the body, in addition to the lungs. It can travel through damaged nasal membranes into the olfactory bulbs just above the nasal passages inside the skull, resulting in loss of the ability to smell and allowing spread to the rest of the brain. The virus can also travel to the brain through the bloodstream. Whichever way the virus enters the brain, it can cause a variety of neurological symptoms such as headache, fainting, stroke, confusion, inflammation of the linings of the brain (meningitis), muscle weakness and seizures.

Early reports highlighted seizures in patients with COVID-19, but now it seems that the incidence of seizures is about what we would expect for any group of critically ill patients. Seizures may occur in anyone with COVID-19, but the rate is increased in people with a pre-existing brain injury, such as a stroke. The good news is that the actual number of people with COVID-19 who develop seizures is low. Whether or not some of these people will continue to experience seizures after recovery is not yet known.

For people who already have epilepsy before experiencing COVID-19, the risk for increased seizures during illness also appears to be low. In a survey of epilepsy specialists, a third of the responding doctors had patients with epilepsy who experienced COVID-19, and most noted no change in their patients’ seizure frequency during the illness. The doctors did, however, voice concern for their patients regarding increased stress, lack of access to specialty care, increase in sleep disturbances and medication shortages, since all these factors can provoke seizures in people with epilepsy.

For anyone who experiences seizures while ill with COVID-19, treatment with antiseizure medication is required. Patients with serious illness may also require drugs to treat the virus and resultant inflammation, and doctors must carefully manage all the medications to prevent side effects and minimize drug interactions. Communication with medical experts is important throughout recovery. Fortunately, access to the medical community has improved since the onset of the pandemic with the rise in virtual visits.

All of us must do what we can to help ourselves and others get through the remaining months of the pandemic until a vaccine becomes available and widespread immunity is established. For people with epilepsy, the following action steps are especially important.

  • Take all doses of your antiseizure medication(s) regularly as prescribed.
  • Communicate closely with your doctor to maintain the best possible seizure control.
  • Maintain a good sleep and exercise schedule for overall well-being.
  • Be proactive and receive the flu vaccine.
  • Protect yourself from getting sick by practicing social distancing, facial masking and proper hand hygiene.

Source Article

Read more

Moderna’s COVID-19 Vaccine Will Cost As Much As A Flu Shot, says CEO Stephane Bancel

KEY POINTS

  • The vaccine candidate will cost between $25 and $37, depending on orders: Moderna CEO
  • The vaccine needs to be administered in two doses
  • Trials of Moderna’s vaccine candidate showed 95% efficiency rates

Massachusetts-based biotechnology firm Moderna’s COVID-19 vaccine candidate, mRNA-1273, will cost governments between $25 and $37 per dose, depending on their orders, CEO Stephane Bancel told a German weekly paper.

“Our vaccine…costs about the same as a flu shot, which is between $10 and $50,” Bancel told Welt am Sonntag (WamS), according to Reuters.

Moderna is in discussion with the European Commission to finalize a deal on the supply of millions of doses of its vaccine at a price less than $25 per dose. “Nothing is signed yet but we are close to a deal with the EU Commission. We want to deliver to Europe and are in constructive talks,” Bancel told the paper. He said it would be a matter of days before an agreement is reached.

This would come up to at least $50 per patient, as the vaccine needs to be administered in two doses. Moderna received nearly $1 billion in funds from the Biomedical Advanced Research and Development Authority for the vaccine, as per Forbes.

The cost of this vaccine will be similar to the price of the annual flu vaccine in the U.S., which costs about $40 for people without insurance. It is interesting to note that flu shots have an efficacy rate of 40%-60%, whereas Moderna is claiming that its vaccine candidate showed an almost 95% efficacy rate in trials. The final Phase 3 trials will confirm these results.

When Moderna announced these results, Dr. Anthony Fauci, the nation’s top infectious disease expert, told NBC News, “These are obviously very exciting results. It’s just as good as it gets… 94.5% is truly outstanding.”

Vaccinations could begin in the second half of December, Fauci said. The vaccine will first be made available to high-risk groups, and for the rest of the population, it will be available next spring.

The government also wants to ensure that everyone can afford a COVID-19 vaccine. Centers for Medicare and Medicaid Services are discussing a rule that as soon as a vaccine is available for the virus and is approved by the Food and Drug Administration, it will be made available to seniors and low-income people in public health insurance programs for no cost.

Moderna is the second company to develop a vaccine, following Pfizer and its partner BioNTech, which proved to be 90% effective in its initial trials.

US biotech firm Moderna says its experimental vaccine is almost 95 percent effective in protecting people from the novel coronavirus US biotech firm Moderna says its experimental vaccine is almost 95 percent effective in protecting people from the novel coronavirus Photo: AFP / Joseph Prezioso

Source Article

Read more

New Zealand offers Biden tips on COVID-19 after successful response

New Zealand’s prime minister said she has offered to help President-elect Joe Biden manage his response to the coronavirus pandemic once he is inaugurated.



a woman wearing glasses: New Zealand offers Biden tips on COVID-19 after successful response


© Getty Images
New Zealand offers Biden tips on COVID-19 after successful response

“I offered to him and his team access to New Zealand health officials in order to share their experience on things we’ve learnt on our COVID-19 journey,” Jacinda Ardern said on Monday, according to Reuters.

New Zealand has garnered international praise for its response to the pandemic, with fewer than 100 current cases reported in the country as of this week. Ardern implemented strict nationwide lockdown measures twice this year, a decision public health experts credit with being instrumental to slowing the spread of the virus.

President Trump, however, has been critical of lockdown measures, warning they have a negative impact on other aspects of public life such as the economy and mental health.

Video: Azar touts Trump administration’s efforts on COVID-19 vaccine (FOX News)

Azar touts Trump administration’s efforts on COVID-19 vaccine

UP NEXT

UP NEXT

Biden has resisted calls from public health officials in the U.S. to implement a national lockdown, instead insisting he would “listen to the scientists” in attempting to get the virus under control.

Members of the Biden transition team have warned that a refusal by Trump to concede the election and begin coordination on coronavirus response could have deadly consequences.

“If we have to wait until Jan. 20 to start that planning, it puts us behind,” Biden said earlier this month. “More people may die if we don’t coordinate.”

New Zealand, a country of 4.8 million people, has reported fewer than 2,100 cases of coronavirus this year with only 25 deaths. The United States, with a population of more than 300 million, has reported over 12.3 million cases and more than 200,000 Americans have died.

Continue Reading

Source Article

Read more